The new treatment offers a median overall survival of 29.3 months for eligible AML patients and 10.3 months for those with intrahepatic cholangiocarcinoma, according to clinical data cited by the comp ...
An expert panel now recommends using certain personalized therapies in the frontline setting for older adults with FLT3- and IDH1-mutant disease.
TIBSOVO is a targeted therapy that works against an abnormal protein created by a mutation in the IDH1 gene. This abnormal protein plays an important role in the development of AML because it prevents ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback